Bioinformatics-based Prediction of Schaftoside Remission in Liver Disease with Cholestasis and Steatosis  

作　　者：Yueping ZHI Kefeng ZHANG Ya GAO Bo LI Houkang CAO 

机构地区：[1]Key Laboratory of Pharmacology for Prevention and Treatment of High Incidence Diseases in Guangxi Higher Education Institutions,Guilin Medical University,Guilin 541199,China

出　　处：《Medicinal Plant》2025年第2期55-57,61,共4页药用植物(英文)

基　　金：Supported by Qingmiao Talent Funding Research Project of Guangxi Province;National College Student Innovation and Entrepreneurship Training Program(202310601031).

摘　　要：[Objectives]To explore the target and mechanism of Schaftoside on cholestasis and steatosis based on network pharmacology and molecular docking.[Methods]The targets of"cholestasis"and"steatosis"were predicted using databases(OMIM and GeneCards),and the key targets were obtained after screening the retrieval data.The binding relationship between Schaftoside and key targets was analyzed by molecular docking.[Results]There were 3370 and 4433 targets for"cholestasis"and"steatosis",respectively,and 1767 overlapping genes were obtained.The results of molecular docking showed that Schaftoside had high binding energy with key targets.[Conclusions]Schaftoside can alleviate cholestasis and steatosis by regulating SREBP-1,CYP7,PPAR-gamma and other key targets to protect liver.

关 键 词：CHOLESTASIS STEATOSIS Schaftoside 

分 类 号：R285[医药卫生—中药学]